Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Novel Therapeutics Have Revolutionized Multiple Myeloma Treatment

February 2nd 2012

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

Bortezomib Approved for Subcutaneous Injection

January 24th 2012

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

Update on Bone Disease in Multiple Myeloma

December 19th 2011

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Refining Maintenance Therapy for Multiple Myeloma

November 21st 2011

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

Dr. Berenson Discusses the Carfilzomib Toxicity Profile

November 18th 2011

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

Novel Drugs and Combinations Promise to Improve Outcomes for Patients With Myeloma

November 14th 2011

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.

Dr. Berenson on Carfilzomib for Multiple Myeloma

November 10th 2011

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

Living With Multiple Myeloma: Nurses as the Lifeline

October 7th 2011

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, "softball-sized tumor pressing against your spinal canal."

Back on the Horse: Ron Rogers

August 24th 2011

You'd never know that Rogers has had multiple myeloma for almost 11 years -- and that's just the way he likes it.

Updates on Multiple Myeloma Diagnosis and Treatment Strategies

August 23rd 2011

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

Accelerating Changes in Oncology

August 12th 2011

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.

Novel Therapies Usher in New Era

July 26th 2011

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

Climbing to New Heights: James Berenson, MD, and the Institute for Myeloma and Bone Cancer Research

May 27th 2011

Oncologist James Berenson, MD, likes all of his patients, especially the ones with whom he skis.

NCCN's 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 24th 2011

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Revlimid Results for Multiple Myeloma Deemed "Historic"

May 6th 2011

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

38 Multiple Myeloma Tumor Genes Mapped

May 5th 2011

Researchers have sequenced 38 tumor genomes from patients with multiple myeloma (MM), comparing them with normal DNA.

Dr. Berenson on the Study of Zometa in Multiple Myeloma

March 15th 2011

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

Dr. Siegel Discusses Ongoing Myeloma Clinical Trials

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

Dr. Siegel on His Presentation at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.